Core Viewpoint - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog, aimed at enhancing drug accessibility and supporting innovation in the pharmaceutical industry [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases like diabetes (12 drugs), anti-infective drugs (13 drugs), and rare diseases (10 drugs), while 29 drugs were removed due to better alternatives [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment reflects a comprehensive coverage of diseases, addressing clinical pain points and improving access to previously unavailable treatments for conditions like triple-negative breast cancer and pancreatic cancer [2]. Group 2: Policy Implementation and Access - To address the issue of new drugs being listed but not available in hospitals, the policy mandates that all designated medical institutions must include new drugs in their procurement catalogs by the end of February 2026, with provisions for temporary green channels if necessary [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one drug, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovative Drugs - Among the new drugs added to the basic medical insurance catalog, 50 are classified as category 1 innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The catalog includes both domestic innovative products and foreign original research products, enhancing the diversity of available treatments [4]. Group 4: Commercial Health Insurance Innovations - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that fill gaps in existing coverage, such as CAR-T cell therapies and treatments for rare diseases prevalent in children [7]. - This catalog complements the basic medical insurance, allowing pharmaceutical companies to expand their market reach while reducing the financial burden on patients [7]. Group 5: Industry Impact and Future Directions - The policy signals strong government support for independent innovation and encourages pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure effective implementation of the drug catalogs, ultimately improving the clinical medication needs of insured individuals [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment aims to address clinical treatment gaps and enhance drug accessibility for patients, particularly for previously hard-to-treat conditions like triple-negative breast cancer and pancreatic cancer [2][4]. Group 2: Policy Implementation - A combination of policies will ensure that newly added drugs are available in hospitals by February 2026, including the establishment of temporary green channels for procurement [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one product, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovation - Among the new drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The inclusion of both domestic and foreign innovative products in the catalog reflects a commitment to enhancing drug accessibility and supporting pharmaceutical innovation [4]. Group 4: Commercial Health Insurance - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that complement the basic medical insurance offerings [7]. - The catalog features advanced therapies such as CAR-T cell treatments and drugs for rare diseases, which are expected to reduce patient financial burdens and enhance market attractiveness for pharmaceutical companies [7][8]. Group 5: Future Directions - The policy signals strong government support for independent innovation and aims to encourage pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Administration plans to refine policies and strengthen management to ensure the effective implementation of the drug catalogs, enhancing public access to necessary medications [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2] Group 1: Drug Inclusion and Coverage - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2] - The total number of drugs in the national medical insurance catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - The inclusion of innovative drugs addresses clinical gaps, such as previously untreatable conditions like triple-negative breast cancer and pancreatic cancer, enhancing patient access to necessary treatments [2][4] Group 2: Policy Implementation and Access - To address the issue of newly included drugs not being available in hospitals, the policy mandates that all designated medical institutions must include new drugs in their procurement catalogs by the end of February 2026, with provisions for temporary green channels if necessary [3] - Negotiated drugs will not be subject to administrative restrictions like "one drug, two regulations" or total medical insurance expenditure limits, facilitating quicker access to high-value innovative drugs [3] Group 3: Innovation and Market Dynamics - Among the newly added drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement in the healthcare system [4][5] - The 2025 catalog includes both domestic innovative products and foreign original research products, reflecting a commitment to enhancing drug accessibility and supporting innovation [4] Group 4: Commercial Health Insurance Innovations - The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, primarily high-innovation treatments for conditions like neuroblastoma and Gaucher disease, which are often prevalent in children [7] - The commercial insurance catalog complements the basic medical insurance, allowing pharmaceutical companies to expand their market presence while reducing patient financial burdens [7][8] Group 5: Future Directions and Industry Impact - The policy signals strong government support for independent innovation and aims to ensure that the value of innovations is recognized and rewarded, encouraging pharmaceutical companies to invest more in original and differentiated research [8] - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication experience for insured individuals [8]

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6] Group 1: Drug Catalog Adjustments - The adjustment of the National Medical Insurance Drug Catalog adheres to principles of supporting genuine innovation and differentiated innovation, aiming to meet diverse medication needs and enhance accessibility to high-value innovative drugs [1][2] - The updated catalog includes 36 cancer drugs, 12 chronic disease medications, 13 anti-infection drugs, and 10 rare disease treatments, increasing the total number of drugs in the catalog to 3,253 [1][2] - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals, rising from 76% in 2024 to 88% in 2025 [3][4] Group 2: Policy Implementation and Impact - The National Medical Insurance Bureau has adjusted the drug catalog for eight consecutive years, adding a total of 949 new drugs, with expenditures exceeding 460 billion yuan and sales exceeding 600 billion yuan during the negotiation period [2][3] - New policies require medical institutions to include newly added drugs in their procurement lists by the end of February 2026, addressing the issue of drugs being listed but not available in hospitals [2][3] Group 3: Commercial Health Insurance Innovative Drug Catalog - The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, primarily high-innovation and clinically valuable treatments, which complement the basic medical insurance offerings [6][7] - The catalog features advanced therapies such as CAR-T cell treatments and bispecific antibodies, targeting rare diseases prevalent in children, thus expanding market opportunities for pharmaceutical companies [6][7] Group 4: Industry Response and Future Outlook - The policy sends a clear signal of government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7] - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication experience for insured individuals [7]

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6]. Summary by Sections Drug Inclusion and Coverage Expansion - The basic medical insurance catalog includes 114 new drugs, with 36 for cancer, 12 for chronic diseases like diabetes, 13 for anti-infection, and 10 for rare diseases, while 29 drugs were removed due to better alternatives [1]. - The total number of drugs in the national medical insurance catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1]. Innovation and Market Impact - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals to 88%, up from 76% in 2024, indicating a shift towards strategic and value-based purchasing in medical insurance [3][4]. - Notable foreign innovative products, such as Novartis' and Johnson & Johnson's drugs, have also been included, highlighting the commitment to enhancing drug accessibility [3]. Policy Measures for Drug Accessibility - To address the issue of newly included drugs not being available in hospitals, the policy mandates that medical institutions must include these drugs in their procurement lists by the end of February 2026 and allows for temporary green channels if necessary [2]. - Negotiated drugs will not be subject to administrative restrictions, ensuring better access for patients [2]. Commercial Health Insurance Innovations - The first commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that exceed basic insurance coverage, thus addressing gaps in clinical drug availability [6]. - The drugs listed are primarily from the 2021-2025 period and include advanced therapies for rare diseases, enhancing market appeal and patient access [6]. Industry Response and Future Directions - The policy signals strong government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7]. - The National Medical Insurance Bureau plans to refine policies and strengthen management to ensure the effective implementation of the new drug catalogs, ultimately improving public access to necessary medications [7].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Viewpoints - The GLP-1 weight loss drugs are experiencing explosive growth globally and in China, with significant sales figures expected for the year [7] - The pharmaceutical and biotechnology industry index increased by 1.50%, ranking 16th among 31 primary industries, underperforming the CSI 300 index [5][15] - The industry PE (TTM) as of May 9, 2025, is 26.77x, showing an upward trend but still below the average [20] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.50%, ranking 16th among 31 primary industries, underperforming the CSI 300 index which increased by 1.56% [5][15] - The medical equipment and pharmaceutical distribution sectors showed the highest gains, with increases of 3.92% and 2.38% respectively, while medical research outsourcing saw a decline of 0.65% [5][15] - As of May 9, 2025, the PE (TTM) for the pharmaceutical and biotechnology industry is 26.77x, up from 26.34x in the previous period, indicating a valuation increase [20] Investment Suggestions - The current trend in GLP-1 weight loss drugs indicates a golden development period for the industry, with significant sales growth expected both globally and in China [7] - The report suggests focusing on companies with solid clinical data, sufficient production capacity, and integrated supply chain capabilities [7] Important Industry News - The NMPA has released new regulations for the quality management of online sales of medical devices, effective from October 1, 2025 [25] - The approval of the first long-acting analgesic new drug in China, "Meloxicam Injection," marks a significant milestone in the industry [31] - Johnson & Johnson's "Guselkumab Injection" has been approved as the first IL-23 inhibitor for treating ulcerative colitis in China [33] - The investment of 2.04 billion RMB by Roche in a new biopharmaceutical production base in Shanghai highlights the ongoing commitment to local production and supply chain enhancement [43]

Policy Developments - The new draft of the "Further Optimization of Drug Procurement Policy" has circulated in the industry, emphasizing the procurement of medical consumables alongside drugs, enhancing policy flexibility [1] - Since the implementation of the "4+7" volume-based procurement in 2018, the government has organized 10 batches of drug procurement and 5 batches of high-value medical consumables procurement, successfully procuring a total of 435 types of drugs [1] Drug and Device Approvals - Johnson & Johnson's Guselkumab has received approval for a new indication in China for treating moderate to severe active ulcerative colitis in adults who have inadequate response to traditional therapies or biologics [2] - Fosun Pharma's subsidiary has received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia, with a cumulative R&D investment of approximately 0.17 million yuan by April 2025 [3] - Reindeer Biologics announced that its CAR-T cell therapy product, Ikigai, has received orphan drug designation from the Saudi FDA for treating relapsed or refractory multiple myeloma in adults [4] Capital Markets - HAYA Therapeutics has completed a $65 million Series A financing round to accelerate the clinical development of its long non-coding RNA-targeted candidate drug HTX-001 for heart failure [5] Regulatory Actions - Pace Double Forest Biopharmaceuticals received administrative regulatory measures from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [6] - Maiwei Biotech's chairman received a notice of investigation from the China Securities Regulatory Commission for suspected short-term trading, which is not expected to significantly impact the company's daily operations [7] - Tibet Weixin Pharmaceutical's subsidiary has withdrawn its drug registration application for a pediatric compound amino acid injection, which is not yet marketed in China [8]